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A B S T R A C T   
Cadmium exposure has been associated with cardiovascular disease. Cigarette smoking is a key source of cad-
mium exposure and thus a potential confounder in observational studies of environmental cadmium and car-
diovascular disease that include tobacco smokers. We leveraged up to 20 years of follow-up in the Danish Diet, 
Cancer and Health cohort to test the hypothesis that cadmium exposure is associated with acute myocardial 
infarction (AMI) among people who never smoked. Between 1993 and 1997, 19,394 never-smoking participants 
(ages 50–64 years) were enrolled and provided a urine sample. From this sample, we randomly selected a 
subcohort of 600 males and 600 females. We identified 809 AMI cases occurring between baseline and the end of 
2015 using the Danish National Patient Registry. We quantified cadmium, creatinine, and osmolality in baseline 
urine samples. Using an unweighted case-cohort approach, we estimated adjusted hazard ratios (aHR) for AMI in 
Cox proportional hazards models with age as the time axis. Participants had relatively low concentrations of 
urinary cadmium, as expected for never smokers (median = 0.20; 25th, 75th = 0.13, 0.32 μg cadmium/g 
creatinine). We did not find strong evidence to support an association between higher urinary cadmium and AMI 
when comparing the highest versus lowest quartile (aHR = 1.16; 95% CI: 0.86 – 1.56) and per IQR increment in 
cadmium concentration (aHR = 1.02; 95% CI: 0.93 – 1.12). Results were not materially different across strata 
defined by sex. Results were generally similar using creatinine or osmolality to account for differences in urine 
dilution. While cadmium exposure has been identified as a risk factor for cardiovascular disease, we did not find 
strong evidence that urinary cadmium at relatively low-levels is associated with AMI among people who have 
never smoked.   
1. Introduction 
Cadmium is a highly persistent, naturally-occurring heavy metal. In 
addition to background levels found in soil, application of phosphate 
fertilizers and sewage sludge to cropland increases the amount of 
cadmium absorbed by foodstuffs and tobacco (Järup and Åkesson, 
2009). As a result, cadmium is present in virtually all foods, with more 
than 80% of food-derived cadmium coming from cereals, vegetables, 
and potatoes (Olsson et al., 2005). Average cadmium intake in food 
varies from 8 to 25 μg/day, and an individual absorbs approximately 1 
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μg/day of cadmium from smoking 20 cigarettes per day (Järup and 
Åkesson, 2009; Sahmoun et al., 2005). 
Cadmium has been recognized as an occupational health hazard for 
decades, most notably as a risk factor for lung cancer, impaired renal 
function, and bone disease (Amzal et al., 2009; Järup and Åkesson, 
2009; Murata et al., 1970; IARC, 1993). At lower levels of exposure more 
relevant for the general population, there is growing evidence of cad-
mium as a cardiovascular risk factor (Chowdhury et al., 2018; Domingo- 
Relloso et al., 2019). Experimental studies have demonstrated cad-
mium’s ability to damage vascular tissues (Abraham et al., 2000; Fuji-
wara et al., 1998; Jeong et al., et al., 2004), induce endothelial 
dysfunction (Dong et al., 2014; Pearson et al., 2003; Prozialeck, 2000; 
Prozialeck et al., 2006; Wang et al., 2018; Woods et al., 2008), and 
promote atherosclerosis (Hernández and Macia, 1996; Kaji et al., 1994; 
Knoflach et al., 2011; Messner et al., 2009; Oliveira et al., 2019; 
Yamamoto et al., 1993). 
The first case report of cadmium-associated acute myocardial 
infarction (AMI) is from a worker exposed to cadmium fumes in 1970 
(Zavon and Meadows 1970). Prospective epidemiologic studies initially 
investigated the relationship of cadmium biomarkers with coronary 
heart disease (CHD) and most (Barregard et al., 2016; Menke et al., 
2009; Tellez-Plaza et al., 2012; 2013a, systematic review: 2013b) – but 
not all (Nawrot et al., 2008) – show positive associations, with Menke et 
al reporting these positive associations among men but not women 
(Menke et al., 2009). One of these prospective studies suggests a positive 
association between blood cadmium and AMI specifically, but these 
results are not consistent with studies using dietary estimates of cad-
mium exposure (Julin et al., 2011; 2013a; 2013b). 
Cadmium is found in cigarettes and smoking is an established risk 
factor for AMI. Therefore, smoking stands to be an important source of 
residual confounding in existing observational studies of relations be-
tween cadmium and AMI. Two prior prospective studies of cadmium 
biomarkers and AMI or CHD among never smokers suggest cadmium is 
associated with AMI, but these studies were underpowered (Barregard 
et al., 2016; Tellez-Plaza et al., 2013a). Quantifying the risk of AMI 
associated with cadmium from sources other than smoking is critical for 
policy-makers considering regulating key dietary or industrial sources of 
cadmium exposure. Accordingly, to investigate whether cadmium is 
associated with AMI independent of smoking, we conducted a case- 
cohort study among people who never smoked tobacco in the Danish 
Diet, Cancer and Health (DCH) cohort. We chose a case-cohort design to 
efficiently leverage stored urine samples collected at baseline, along 
with existing data from up to 20 years of follow-up. 
2. Methods 
We used existing data and urine samples from the prospective DCH 
cohort to evaluate the association between urinary cadmium concen-
trations and AMI among men and women who never smoked. Details of 
sampling, recruitment, and follow-up procedures for the DCH cohort are 
provided elsewhere (Tjønneland et al., 2007). Briefly, between 
December 1993 and May 1997, 160,725 individuals (ages 50–64 years) 
living in the area surrounding Copenhagen or Aarhus were invited to 
participate in the study, 57,053 (35.5%) of which consented to partici-
pate. At enrollment, participants completed questionnaires to assess 
smoking habits, socioeconomic characteristics, diet, and physical ac-
tivity. Trained research personnel also collected anthropometric mea-
surements and urine samples. The DCH cohort was established in 
accordance with the Helsinki Declaration and approved by the local 
Ethics Committees. Written informed consent was obtained from all 
participants. 
For this study, we excluded from analyses participants with preva-
lent cancer at baseline (n = 581), missing a urine sample because it was 
not provided (n = 390) or not available in the biobank (n = 772), or 
missing information on self-reported smoking status (n = 69) (Fig. 1). 
Among the remaining participants, only participants who self-identified 
at baseline as never smokers (n = 19,394 total; n = 6,821 men and n =
12,573 women) were eligible for inclusion. 
Among all eligible participants who never smoked, we identified AMI 
cases that occurred between individual enrollment dates and December 
31st, 2015 using the Danish National Patient Registry (NPR) (Schmidt 
et al., 2015; Lynge et al., 2011). The Danish National Health Service 
provides free universal tax-supported health and hospital care for all 
residents. Since 1977, all patient diagnoses in somatic hospitals have 
been recorded in the NPR and coded using ICD 8 (prior to 1994) or ICD 
10 (implemented in 1994). Beginning in 1995, diagnoses from emer-
gency rooms and outpatient visits were also included in the NPR 
(Schmidt et al., 2015; Lynge et al., 2011). Using the unique civil regis-
tration number assigned to all Danes at birth, we identified DCH cohort 
participants registered with a diagnosis of AMI in the NPR (primary or 
secondary diagnosis of ICD-8 410–410.99, 427.27 and ICD-10: I21.0- 
I21.9 and I46.0-I46.9) (Pedersen, 2011; Schmidt et al., 2014). From 
study baseline through 2003, a physician with experience in cardiology 
reviewed the medical records of potential AMI cases and confirmed di-
agnoses according to AMI criteria set by the American Heart Association 
and the European Society of Cardiology for use in epidemiology. The 
positive predictive value of this approach was greater than 92% (Joen-
sen et al., 2009). Therefore, beginning in 2004, participants identified 
through the NPR as having an AMI were accepted as cases without 
further adjudication. Cases of cardiac arrest (ICD-8: 427.27 or ICD-10: 
I46.0-I46.9) were an exception and were only included if deemed to 
be of cardiac origin by a skilled physician through 2013 (Monrad et al., 
2017). Through 2013 we used the Danish Cause of Death Registry to 
identify fatal AMI cases that were not included in the NPR. Between 
2013 and 2015, we identified additional DCH participants with AMI 
using ICD codes registered in the NPR. 
We identified a total of 809 cases of incident AMI among all eligible 
participants who never smoked. We selected a referent subcohort by 
randomly sampling 600 men and 600 women (total n = 1,200) who 
never smoked, and 61 of these subcohort members were AMI cases. We 
censored participants at the emigration date recorded in the Danish 
Central Person Registry, the date of death documented in the Danish 
Cause of Death Registry, or December 31st, 2015, whichever occurred 
first (Helweg-Larsen, 2011; Pedersen, 2011; Schmidt et al., 2014). 
2.1. Urinary Cadmium, Creatinine, and osmolality 
Spot urine samples were collected in a transparent polypropylene 
cup at baseline using trace metal-free techniques (Tjønneland et al., 
2007). Within 2 hours of collection, a laboratory technician aliquoted 
urine samples and stored them in the biobank at − 150 ◦C. The urine was 
never in contact with any metal equipment nor any colored plastic (dyes 










- 19,916 Current smokers
- 15,931 Former smokers
Excluded
- 581 Prevalent cancer
- 1,162 No urine sample
- 69 No smoking status
19,394
Never smokers
Fig. 1. Flow diagram of case-cohort study design with participants from the 
Diet, Cancer and Health cohort (Copenhagen and Aarhus, 
Denmark; 1993–1997). 
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and subcohort members were mixed and anonymized before shipment 
on dry ice to RTI International’s Trace Metals Laboratory (Research 
Triangle Park, NC) to ensure completely blinded analysis and to account 
for potential batch to batch variation in urine analysis. 
High purity HNO3 was prepared from trace metals grade concen-
trated nitric acid (JT Baker, Phillipsburg, NJ) by acid distillation 
(Milestone DuoPur, Shelton, CT) and screened for impurities before use. 
National Institute of Standards and Technology (NIST, Gaithersburg, 
MD) traceable stock standards of analytes and internal standards (bis-
muth, praseodymium, holmium, scandium, and yttrium) were pur-
chased commercially (High Purity Standards, Charleston, SC) and used 
to prepare calibration standards. High-purity deionized water (16MΩ or 
better, Pure Water Solutions) was used for preparation of all samples and 
standards. 
Urine samples were thawed to room temperature and vortexed to 
mix thoroughly. A 0.50 mL aliquot of each sample was transferred to 15- 
mL polypropylene tubes. We added 0.50 mL HNO3 and 0.050 mL of 
concentrated HCl to each digestion vessel and heated in a graphite 
heating block (SCP Science, Baie d’Urfe, Quebec) at 95 ◦C for 30 min. 
Samples were allowed to cool to room temperature and we added 0.25 
mL of 30% hydrogen peroxide solution (EMD Millipore, Burlington, 
MA). The resulting mixture was digested at 95 ◦C for an additional 30 
min. Tubes were cooled to room temperature, spiked with an internal 
standard mixture to a final concentration of 5 µg/L, and diluted to a final 
volume of 5 mL with deionized water with mixing. 
An iCAP Q ICP-MS system (Thermo Scientific, Waltham, MA) 
equipped with a helium gas collision cell was used for the determination 
of a suite of 19 elements including cadmium. The instrument was tuned 
daily to maximize sensitivity and signal stability across the mass range 
and to mitigate polyatomic interferences. We monitored multiple iso-
topes for most elements to account for analytical interferences (poly-
atomic and isobaric), such as molybdenum for cadmium (MoO). 
NIST standard reference material (SRM) 2668 – Toxic Elements in 
Frozen Human Urine was used as a quality control sample to verify 
method accuracy and reproducibility. Mean recovery for cadmium in 
NIST SRM 2668 was 99.1% with a coefficient of variation (CV) of 4.2% 
over 47 sample batches and 9 months. Approximately 10% of samples 
were reanalyzed to provide an additional measure of method accuracy 
and reproducibility. Samples were selected at random within 3 con-
centration ranges: low (<0.25 µg Cd/mL), medium (0.25–0.50 µg Cd/ 
mL) and high (>0.50 µg Cd/mL) to provide a measure of reproducibility 
across the range of observed sample concentration ranges. These sam-
ples demonstrated good reproducibility of 6.6% CV for samples above 
the LOD and a Pearson’s correlation coefficient of 0.93. 
We quantified urinary creatinine colorimetrically by the Jaffe reac-
tion with a Cayman Chemicals (Ann Arbor, MI) Creatinine Assay Kit 
following the manufacturer’s instructions. NIST SRM 2668 has an 
informational value for creatinine (626 mg/L in Level 1), so it was 
measured as a quality control sample. Recovery of the SRM generally fell 
within 90–110% of the informational value. We reanalyzed ~ 10% of 
samples as incurred samples, and the incurred values exhibited a CV of 
3.9% for samples above the limit of detection. 
We measured urinary osmolality by the freezing point depression 
method using a Model 3320 Micro-Osmometer by Advanced In-
struments, Inc. (Norwood, MA). We measured Clinitrol Reference So-
lution (Advanced Instruments, certified value 290 mOsm) and 800 
mOsm Renol Urine Osmolality Control solution as daily QC samples and 
report CV = 1.3%, 0.7% for the two reference solutions. 
For the main analyses, we used the quantified cadmium concentra-
tions for values below the LOD. Among AMI cases and the subcohort 
members, 17 individuals (2.1%) and 22 individuals (1.8%) had urinary 
cadmium concentrations below the LOD (median LOD [25th, 75th] =
0.003 [0.001, 0.003] μg/L). We calculated creatinine-standardized 
cadmium concentrations by dividing urinary cadmium concentrations 
(μg) by creatinine (g). 
2.2. Urinary cotinine and Self-reported Second-hand tobacco exposure 
We measured urinary cotinine, an indicator of tobacco smoke 
exposure, using a cotinine ELISA bioassay kit by Abnova Corporation 
(Taipei, Taiwan). We followed the manufacturer’s protocol for analysis, 
calibrating the analysis over the range of 0–100 µg cotinine/L urine. 
Incurred sample reanalysis results exhibited a CV of 2.9%. Over-range 
samples were diluted into the linear range with deionized water and 
remeasured. 
At baseline, participants also self-reported secondhand smoke 
exposure at home and at work during each decade of their life prior to 
and at DCH cohort enrollment (ages 0–9, 10–19, 20–29, 30–39, 40–49, 
≥50 years). Using responses to these questions we grouped participants 
based on secondhand smoke exposure level into: 1) none; 2) exposure 
only before age 50 years (i.e. earliest possible age of DCH cohort 
enrollment); and 3) exposure at age 50 years and older (i.e. at 
enrollment). 
2.3. Covariates 
Participants self-reported age, sex, education, and physical activity 
on questionnaires administered at baseline, as previously described 
(Tjønneland et al., 2007). Women self-reported menopausal status and 
parity. At baseline, study personnel measured height and weight, and 
calculated body mass index (BMI). We identified potential confounders, 
sources of selection bias, and covariates to include in statistical models a 
priori based on knowledge about the risk factors for cadmium exposure 
and AMI (Hernán, 2002). 
2.4. Statistical analyses 
We used the Prentice case-cohort approach to estimate associations 
between creatinine-standardized urinary cadmium concentrations and 
AMI (Barlow et al., 1999). In this time-to-event analysis, follow-up for 
each participant in the subcohort started on the age at their specific DCH 
cohort enrollment date and ran until the age at the earlier of date of AMI 
diagnosis or date of censoring due to emigration, death, or the end of the 
follow-up period. AMI cases among DCH participants who were not 
included in the subcohort were not considered to be at risk for AMI until 
immediately preceding the date of AMI diagnosis. Based on the Prentice 
method, we estimated hazard ratios and robust 95% confidence in-
tervals for AMI using Cox proportional hazards models (Barlow et al., 
1999). We used age as the time axis because it is related to the outcome 
and using time-on-study as the axis may bias results, even when 
adjusting for age as a covariate (Thiébaut and Bénichou, 2004). We 
estimated the association between creatinine-standardized cadmium 
and AMI in minimally-adjusted models including sex as a covariate and 
in fully-adjusted models including sex, BMI (continuous-linear term), 
education (categorical), and urinary cotinine concentrations (contin-
uous-linear term). We evaluated the association between quartiles of 
creatinine-standardized cadmium and AMI and conducted a linear test 
for trend by assigning observations in each quartile of creatinine- 
standardized cadmium the median concentration of the quartile, treat-
ing the variable as continuous, and assessing the p-value for this term 
(Rothman et al., 2008). We further assessed the linearity of the rela-
tionship between creatinine-standardized cadmium and AMI by 
modeling cadmium using a natural cubic spline with three degrees of 
freedom (knots at 33rd and 67th percentiles). We visually assessed the 
linearity and ran an ANOVA to compare this spline model to the model 
with a linear term. We assessed the p-value from the ANOVA as the non- 
linearity p-value. 
In secondary analyses, we also included a sex by cadmium product 
term in adjusted models, as well as estimated the association between 
creatinine-standardized urinary cadmium concentrations and AMI in 
sex-stratified analyses. For the strata of women, we included meno-
pausal status as a covariate in adjusted models. In the stratified analysis, 
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we visually evaluated linearity and compared the fit of the linear models 
to spline models with three degrees of freedom, as described for the 
main analysis. 
2.5. Sensitivity analyses 
We conducted a series of sensitivity analyses to assess the robustness 
of our findings to outliers and cadmium concentrations below the LOD. 
First, we repeated the main analyses with all cadmium concentrations 
below the LOD assigned the LOD/sqrt 2 (Hornung and Reed, 1990). 
Separately, we conducted additional analyses restricting the study 
sample to participants with creatinine-standardized cadmium concen-
trations between the 5th and 95th percentiles. 
We conducted a series of sensitivity analyses to evaluate the impact 
of using creatinine standardization to account for variation in urine 
dilution. We compared our results to hazard ratios from adjusted models 
that included creatinine as a covariate. Based on methods described by 
O’Brien et al (2016), we also calculated a covariate adjusted creatinine- 
standardized cadmium ratio (O’Brien et al., 2016). First, we fit a linear 
regression model predicting log creatinine concentrations based on age, 
sex, physical activity level, and BMI. Next, we divided urinary cadmium 
concentrations by the ratio of quantified urinary creatinine concentra-
tions to predicted creatinine concentrations. We report continuous re-
sults per interquartile range difference in the covariate-adjusted 
creatinine-standardized cadmium ratio to facilitate comparison across 
different methods. We also assessed how using osmolality to account for 
variation in urine dilution alters our results. We conducted osmolality- 
adjusted analyses which included osmolality, instead of creatinine, as 
a covariate in adjusted models. We also assessed the impact of using 
osmolality-standardized cadmium concentrations in adjusted models. 
Moreover, we evaluated how using these different methods to account 
for variation in urine dilution altered results from the secondary sex- 
stratified analyses. In models adjusted for creatinine, we evaluated the 
association between sex-specific quartiles of cadmium and AMI. We also 
assessed linearity of the relationship of cadmium with AMI when 
adjusting for creatinine by comparing linear models to natural cubic 
splines with three degrees of freedom (knots at 33rd and 67th percen-
tiles), as described for the main analyses. 
Finally, we excluded participants with prevalent diabetes prior to 
baseline (n = 16 subcohort members and n = 33 non-subcohort AMI 
cases) and additionally adjusted for incident diabetes (n = 187) during 
the follow-up period in the fully-adjusted model. In a separate sensitivity 
analysis, we excluded all participants with diabetes prior to or during 
follow-up. Diabetes could potentially confound the relationship of uri-
nary cadmium concentrations with AMI. However, diabetes and kidney 
function could also be plausible causal intermediaries on a pathway 
between cadmium exposure and cardiovascular disease, and therefore, 
including diabetes as a covariate may result in over-adjustment (Van-
derWeele, 2019). We conducted additional analysis in the fully adjusted 
model: (1) adjusting for hypertension, hypercholesteremia, and dia-
betes; (2) excluding participants with cotinine ≥ 200 µg/L (n = 40 who 
may be current smokers (Kim, 2016); (3) excluding participants with 
creatinine < 0.03 g/L and greater than 3.0 g/L ; and 4) excluding par-
ticipants with heart failure or stroke. 
All analyses were conducted in R version 3.6.2 using the survival 
package and functions to account for the case-cohort study design. 
3. Results 
3.1. Participant characteristics 
We identified 809 cases of AMI, predominantly among males 
(60.3%). Among subcohort members, we censored 3 participants due to 
emigration and 138 due to death (median follow-up time [25th, 75th 
percentile] = 14.3 [8.7, 16.6] years). Participants who subsequently 
developed AMI tended to have a lower level of education and be more 
obese compared with subcohort 
members (Table 1). 
Overall, the median (25th, 75th) cotinine concentration was 16.8 
(5.6, 34.4) µg/L. Participants who reported being exposed to second-
hand smoke at age ≥ 50 years had a higher median cotinine concen-
tration (21.0 [7.5, 39.8] µg/L) compared with participants who reported 
secondhand smoke exposure only prior to age 50 years (8.8 [3.5, 20.8] 
Table 1 
Baseline characteristics of AMI cases and subcohort members.  









Age at enrollment (years) 1200 55.8 (52.5, 
59.9) 
809 58.0 (54.1, 
61.3) 
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µg/L) or no secondhand smoke exposure (10.5 [2.7, 16.9] µg/L). Urinary 
cadmium concentrations at study baseline were similar between males 
and females among both the subcohort and AMI cases (Table 2). 
The median urinary cadmium concentration among females who 
developed AMI was higher compared with the average for females in the 
subcohort, while the median cadmium concentrations among male AMI 
cases was similar to the median for males in the subcohort. Overall, 
males had higher concentrations of urinary creatinine and osmolality, as 
well as lower creatinine and osmolality standardized cadmium con-
centrations compared with females (Supplemental Table 1). 
3.2. Urinary cadmium and AMI 
We observed that the hazard ratio for AMI increased monotonically 
across quartiles of cadmium concentrations, reaching a fully-adjusted 
hazard ratio of 1.16 (95% CI: 0.86 – 1.56) in the highest versus lowest 
quartile (p-trend: 0.19) (Table 3). When considering urinary cadmium 
concentrations as a linear continuous variable, an interquartile range 
difference (0.19 μg/g) in creatinine-standardized cadmium concentra-
tions was associated with a fully-adjusted hazard ratio of 1.02 (0.93, 
1.12). Results were not materially different in minimally and fully- 
adjusted models. Models using spline functions of cadmium did not 
suggest a monotonic exposure–response function (Supplemental Fig. 1). 
3.3. Sex-Specific relationship between cadmium and AMI 
We did not find strong evidence to support an association between 
cadmium and AMI in either sex strata (Table 4; e.g., fully-adjusted 
hazard ratio (aHR) = 1.29; 95% CI: 0.80 – 2.08 for males and aHR =
1.00; 95% CI: 0.63 – 1.60 for females comparing the highest and lowest 
quartiles). Analyses considering cadmium as a linear continuous vari-
able (males: aHR = 1.01; 95% CI: 0.82 – 1.26; females: aHR = 1.02; 95% 
CI: 0.92 – 1.12) or more flexibly using splines (Supplemental Fig. 1) did 
not provide evidence of an association between urinary cadmium and 
AMI for either of the sexes. 
3.4. Sensitivity analyses 
We performed multiple sensitivity analyses to evaluate the robust-
ness of these results to different analytic choices. Results were not 
materially different in sensitivity analyses modeling values of cadmium 
below the LOD with LOD/sqrt 2 rather than with the quantified cad-
mium concentrations or in analyses trimming cadmium values within 
the 5th and 95th percentiles (Supplemental Table 2). However, results 
did differ somewhat depending on the approach used to adjust for 
variation in urine dilution. We observed stronger evidence for an asso-
ciation for creatinine-adjusted and osmolality-adjusted analyses (Sup-
plemental Table 3). For example, we observed fully-adjusted hazard 
ratios of 1.51 (95% CI: 1.03 – 2.20) and 1.33 (95% CI: 0.93 – 1.90) 
comparing the highest versus lowest quartiles in creatinine adjusted and 
osmolality adjusted models, respectively, but fully-adjusted hazard ra-
tios of 1.15 (95% CI: 0.88 – 1.51) and 1.00 (95% CI: 0.76 – 1.32) in 
models using covariate-adjusted creatinine standardization or osmo-
lality standardization, respectively. Models with spline representations 
of creatinine adjusted cadmium concentrations suggested an association 
among both sexes combined and perhaps among women (Supplemental 
Figure 2). Nonetheless, in analyses considering cadmium as a linear 
continuous variable, there was not strong evidence to support an asso-
ciation regardless of the modeling approach, with adjusted hazard ratios 
per IQR ranging from 0.99 to 1.02. 
Regardless of the approach to adjust for variation in urine dilution, 
we did not observe strong evidence of effect modification by sex (Sup-
plemental Tables 4 and 5). The exclusion of prevalent diabetes cases at 
baseline and adjustment for incident diabetes or other CVD conditions 
did not materially change the results (Supplemental Table 6 and 7). The 
exclusion of participants with cotinine concentrations ≥ 200 µg/L, 
extreme creatinine concentrations, or cases of stroke or heart failure, 
also did not meaningfully change our results. 
4. Discussion 
In this case-cohort study of never smokers with up to 20 years of 
follow-up, we did not find strong evidence supporting an association 
between urinary cadmium and AMI. Recent reviews find growing evi-
dence of cadmium exposure as a risk factor for different dimensions of 
CVD, including AMI (Tellez-Plaza et al., 2013b; Tinkov et al., 2018). 
Although prior studies have adjusted for smoking, few have been 
designed to evaluate whether cadmium is associated with AMI at levels 
consistent with populations who have never smoked tobacco. Quanti-
fying this relationship is critical information for policy-makers consid-
ering the value of regulating environmental sources of cadmium 
exposure. Our findings suggest that cadmium is not a substantial risk 
factor for AMI among never-smokers at exposures corresponding to 
urinary levels generally below 0.5 µg/g creatinine. However, we cannot 
exclude the possibility of potentially important but relatively small ef-
fect sizes among this non-smoking population. 
Cadmium’s effects on the vascular endothelium have been known for 
decades, and a number of animal (murine and bovine) and cellular 
studies have suggested a link between cadmium and atherosclerosis and 
hypertension (Prozialeck et al., 2006). Cadmium can induce release of a 
variety of inflammatory markers (Knoflach et al., 2011), stimulate the 
release of antithrombolytic agents and facilitate the adhesion of leuko-
cytes and platelets to the endothelium (Hernández and Macia, 1996; Kaji 
et al., 1994; Yamamoto et al., 1993), and enhance production of extra-
cellular matrix components that increase blood vessel stiffness 
(Abraham et al., 2000; Fujiwara et al., 1998; Jeong et al., 2004). How-
ever, the internal dose of cadmium that will elicit these effects in 
humans has not yet been characterized. 
Prior studies have mostly (Barregard et al., 2016; Menke et al., 2009; 
Tellez-Plaza et al., 2012; 2013a) but not always (Nawrot et al., 2008; 
Jeong et al., 2020) reported positive associations between cadmium 
biomarkers and CHD or ischemic heart disease. Two prospective studies 
report consistent positive association between cadmium biomarkers and 
incident AMI or CHD when adjusting for tobacco use, and among never 
smokers in stratified analyses (Barregard et al., 2016; Tellez-Plaza et al., 
2013a). For example, in the Malmö Diet and Cancer Study, Barregard 
et al. (2016) reported a hazard ratio of 1.7 (95% CI: 1.1 – 2.7) for AMI 
when comparing participants in the highest quartile of blood cadmium 
with participants in the lowest quartile, while adjusting models for 
Table 2 
Urinary cadmium, creatinine and osmolality concentrations by participant sex.   
Subcohort AMI Cases  
Female Male Female Male 
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tobacco smoking. In stratified analyses, among participants who never 
smoked, the authors reported a hazard ratio of 2.4 (95% CI: 1.1 – 5.4) for 
AMI when comparing those in the highest versus lowest quartile of blood 
cadmium, but there were only seven cases in the highest quartile. 
Similarly, in the Strong Heart Study, Tellez-Plaza et al. (2013a) reported 
that higher concentrations of urinary cadmium were associated with 
incident CHD when adjusting for demographics, smoking status, and 
cumulative smoking dose (aHR = 1.22 comparing 80th [1.62 µg/g] with 
20th [0.55 µg/g] percentile of log-transformed creatinine-standardized 
cadmium concentrations; 95% CI: 1.08 – 1.38). These results were 
consistent with those reported among the Strong Heart Study group of 
never smokers with 243 CHD cases (HR = 1.16 comparing 80th with 
20th percentile; 95% CI: 0.96, 1.39). While the mean participant age and 
follow-up duration in these studies were similar, neither are directly 
comparable to our analysis. Specifically, Barregard et al. used 
blood-cadmium while Tellez-Plaza et al. used the broader CHD outcome 
and, on average, participants had higher urinary cadmium concentra-
tions. These two studies, along with a study of cardiovascular mortality 
using NHANES data (Tellez-Plaza et al., 2012), were included in a recent 
meta-analysis by Chowdhury et al., 2018 that reported a relative risk for 
CHD of 1.43 (95% CI: 1.12, 1.84) among never-smoking participants in 
the highest compared to lowest third of cadmium concentrations 
(Chowdhury et al., 2018). Our results, based on 809 cases of AMI, add to 
this existing literature and provide little evidence that at lower con-
centrations of cadmium, commonly observed among never smokers, 
higher urinary cadmium is associated with AMI. 
In our analysis we assessed urinary biomarkers of cadmium expo-
sure. Epidemiologic studies of cadmium benefit from the availability of 
well-established and validated biomarkers of exposure in urine or blood, 
but not in plasma because cadmium is concentrated in red blood cells 
(Yuan et al., 2017). Following exposure, cadmium accumulates in the 
kidneys where it remains for many years (half-life: 10–30 years) (Amzal 
et al., 2009; Fowler et al., 2015). A small portion of cadmium is 
continuously but slowly excreted in urine (Fowler et al., 2015). There-
fore, urinary concentrations of cadmium provide estimates of long-term 
exposure while blood cadmium reflects a combination of both long-term 
and more recent exposures (Nordberg, 2009). As recently reviewed 
(Vacchi-Suzzi et al., 2016), most studies examining temporal variability 
of urinary cadmium suggest that a single spot urine sample is a stable 
estimate (e.g., see Akerstrom et al., 2014; Arisawa et al., 1997; Meliker 
et al., 2019; Smolders et al., 2014; Vacchi-Suzzi et al., 2017). At low 
levels of urine cadmium, we might expect urinary excretion of proteins 
and urinary flow rate to contribute to the variability of creatinine- 
adjusted urine cadmium in spot urine samples making one-time mea-
sures less representative; however, we previously reported an ICC =
0.78 for a small cohort with low levels of urine cadmium (median =
0.21 µg/g) (Vacchi-Suzzi et al., 2017). It is also possible that blood 
cadmium may be a more relevant measure of exposure if cadmium is 
linked with atherosclerosis although this remains to be determined. 
When using urine biomarkers, it is essential to control for differences 
in urine dilution across participant samples, with many options avail-
able but little consensus on the optimal approach. The most widely used 
approaches account for variation in urine dilution by considering uri-
nary creatinine concentrations, even though creatinine concentrations 
can be influenced by muscle mass (Suwazono et al., 2005). In our 
analysis we also measured osmolality – an index of the concentration of 
osmotically active particles, particularly chloride, sodium, urea, and 
potassium – which is strongly correlated (ρ = 0.75) with specific gravity 
(Imran et al., 2010; Voinescu et al., 2002). Various statistical approaches 
have also been applied to adjust for variations in the urine dilution 
measure. Traditionally investigators divide by the measure (e.g., cad-
mium/creatinine), but some have argued for statistical adjustment in a 
regression model (Barr et al., 2005) or adjustment for a covariate- 
adjusted density measure (O’Brien et al., 2016). We chose cadmium/ 
creatinine for our primary analysis, both because it is the most 
commonly used method in prior studies and because of the high degree 
of temporal stability in the measure (intraclass correlation coefficient 
greater than 0.80) in spot samples collected years apart (Meliker et al., 
2019; Vacchi-Suzzi et al., 2016). However, we also report results from a 
series of sensitivity analyses in order to assess the robustness of our re-
sults across different methods of adjusting for variation in urine dilution 
and found that results were generally similar. When cadmium was 
Table 3 















Continuous c 1948 809  1.02 (0.94–1.12) 1.02 (0.93–1.12)  
Quartile 1: less than or equal to 0.13 489 207 0.097 Ref Ref 0.19 
Quartile 2: greater than 0.13 to 0.20 459 183 0.17 0.90 (0.69–1.17) 0.91 (0.69–1.19)  
Quartile 3: greater than 0.20 to 0.32 502 213 0.25 1.10 (0.85–1.44) 1.11 (0.84–1.45)  
Quartile 4: greater than 0.32 498 206 0.43 1.16 (0.86–1.55) 1.16 (0.86 –1.56)   
a Minimally-adjusted model includes sex. 
b Fully-adjusted model includes: sex (categorical), BMI (continuous), education (categorical), and cotinine (continuous). 
c Continuous rate ratio for an interquartile range (IQR) = 0.19 μg/g difference in creatinine standardized urinary cadmium concentration. Interquartile range and 
creatinine standardized cadmium quartiles are based on concentrations among subcohort members. 
Table 4 
Fully-adjusted hazard ratio (HR) for risk of AMI per interquartile range differ-
ence and quartile of urinary cadmium concentration (creatinine standardized) in 



















Continuous a 1040 488 1.01 
(0.82–1.26) 
908 321 1.02 
(0.92–1.12) 
Quartile 1: 
less than or 
equal to 
0.13 
384 172 Ref 105 35 Ref 
Quartile 2: 
greater 
than 0.13 to 
0.20 
316 143 0.97 
(0.71–1.32) 




than 0.20 to 
0.32 
252 125 1.15 
(0.83–1.60) 





88 48 1.29 
(0.80–2.08) 
410 158 1.00 
(0.63–1.60) 
Fully-adjusted model includes: BMI (continuous), education (categorical), and 
cotinine (continuous). Female model also adjusted for menopause status. 
P-value for sex by cadmium product term in fully-adjusted model: p = 0.30. 
a Continuous HR for an interquartile range (IQR) = 0.19 μg/g creatinine dif-
ference. Interquartile range and creatinine standardized cadmium quartiles are 
based on concentrations among subcohort members. 
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treated as a linear continuous variable, a range of point estimates in 
fully-adjusted models (aHR = 0.97–1.02) was observed for the IQR 
increment across the analyses. Results were somewhat more variable 
when considering quartiles of cadmium, and the upper quartile was 
generally elevated more so in the creatinine-adjusted model (Supple-
mental Table 3). Resolving the best strategy for urine dilution adjust-
ment is an important and active area of inquiry for epidemiologic studies 
of urine biomarkers. 
CHD tends to develop later in women compared with men (Maas and 
Appelman, 2010), and presentation of risk factors can also vary by sex 
(Grundtvig et al., 2009; Keteepe-Arachi and Sharma, 2017). Most 
studies have not shown sex differences in the relationship between 
cadmium and CVD outcomes (as reviewed, Tellez-Plaza et al., 2013b; 
Tinkov et al., 2018), however, one study reported associations with CVD 
and CHD mortality in men but not in women (Menke et al., 2009), and 
ours is the first study to soundly investigate sex differences among never 
smokers. More research is needed to better understand potential sex 
differences in relationships between cadmium and CVD health out-
comes, especially in light of higher levels of cadmium in women. Sex 
differences in cadmium levels are thought to reflect lower iron levels, 
which may increase cadmium absorption in the digestive tract (Nishijo 
et al., 2004; Vahter et al., 2007). Future studies may also consider using 
multiple methods to account for variations in urine dilution due to the 
sex differences in creatinine concentrations and osmolality. 
Our study has several limitations. We adjusted statistical models for 
covariates that we selected a priori, but residual confounding due to 
other characteristics that we did not control for is always possible. It is 
also possible that our results are impacted by selection bias due to non- 
participation in the DCH cohort. Like many studies, participants tended 
to be better educated, wealthier, more often in white-collar jobs, and 
more likely to be married than their non-participating counterparts 
(Tjønneland et al., 2007). Furthermore, we identified incident AMI using 
national registries and based on diagnosis codes, which could result in 
some misclassification of the outcome. We were not able to examine the 
pathophysiologic etiology (atherosclerosis vs other) of the AMI di-
agnoses in detail due to the lack of information extracted from the NPR. 
Given the documented high specificity of our approach to outcome 
assessment, we expect this misclassification to increase the variance in 
the estimated relationship of urinary cadmium and AMI but not 
considerably bias the results. We also did not identify prevalent AMI 
among subcohort members who did not have an additional diagnosis of 
AMI in the NPR during the follow-up period. However, the prevalence of 
AMI at baseline in the DCH cohort at baseline was<2%; therefore, we 
expect this misclassification to be small. We were powered to detect a 
hazard ratio of 1.3 in the main analysis by quartiles, however we 
observed a hazard ratio of 1.16 with wide confidence intervals. There-
fore, we cannot exclude the possibility that with a larger sample size our 
inferences may have been different. Lastly, it is possible that for some 
participants in the subcohort and larger DCH cohort death may have 
precluded AMI, and therefore could be considered a competing risk that 
would bias our results. However, we do not expect this to substantially 
impact our results since few subcohort members were censored due to 
death and the median follow-up time for subcohort members who died 
was slightly longer than the follow-up duration for participants who 
were AMI cases (median [25th, 75th] = 12.2 [7.1, 16.6] years). 
Our study sample is predominantly non-Hispanic white, and there-
fore the results may not be generalizable to other racial and ethnic 
groups. We expect our results to be generalizable to other Scandinavian 
and non-Hispanic white populations of never smokers. Cadmium expo-
sure among this sample of never smokers is likely to be similar to, or 
lower than, levels reported for never smokers in the United States 
(Riederer et al., 2013). 
Our study also has several strengths. We used the urine cadmium 
biomarker as a proxy for exposure. This biomarker is an indicator of 
body burden in the kidney, is temporally stable, and reflects key sources 
of exposure such as those from diet or cigarettes (Amzal et al., 2009; 
Fowler et al., 2015; Vacchi-Suzzi et al., 2016). Estimating exposure to 
key dietary sources of cadmium via a food frequency questionnaire has 
proved challenging because of the diverse foodstuffs that accumulate 
cadmium from application of phosphate fertilizers and sewage sludge 
(Singh, 1994; Vacchi-Suzzi et al., 2015), further pointing to the utility of 
the urinary cadmium biomarker as a proxy for exposure. Another 
strength of our study is that we used multiple approaches to account for 
urine dilution. Additionally, we used data from a prospective, 
population-based cohort with a long follow-up period. This prospective 
design and use of national registry for case identification can reduce the 
likelihood that disease status would influence participation or that dif-
ferences in participant characteristics would impact the reporting of 
disease status. Furthermore, urine was collected before diagnosis. We 
also assessed tobacco smoking behaviors and secondhand tobacco 
smoke exposure history at baseline, which are potential confounders. 
4.1. Conclusions 
The results of this prospective study among people who never 
smoked did not provide strong evidence to support the presence of an 
association between higher cadmium exposure and AMI at levels of 
urine cadmium < 0.5 µg/g creatinine; however, we also cannot rule out 
the possibility that there is a small association that we were under-
powered to detect. Future studies considering sex differences in the 
relationship between cadmium and CHD or AMI may want to use mul-
tiple methods to account for variations in urine dilution given the 
observed sex-differences in cadmium, creatinine, and osmolality. 
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